Sign inCreate account

Report workspace tools

NCT01136876COMPLETEDanonymous

Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin as New Biomarker in Patients With Moderate Fall in eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320

Sponsor

Source record

Bracco Diagnostics, Inc

Phase

Source record

PHASE4

Modality

AI-normalized

small molecule

Target

AI-normalized

Iopamidol, Iodixanol-320

Indication / condition

AI-normalized

Coronary Artery Stenosis

Intervention

Source record

Iopamidol, Iodixanol-320

Source & freshness

Source record

NCT ID

NCT01136876

Original source

ClinicalTrials.gov

Source last updated

Nov 04, 2020

Ingested at

Jun 05, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01136876

Title

Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin as New Biomarker in Patients With Moderate Fall in eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320

Sponsor

Bracco Diagnostics, Inc

Status

COMPLETED

Phase

PHASE4

Condition raw

Coronary Artery Stenosis

Condition normalized

Coronary Artery Stenosis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Iopamidol, Iodixanol-320

Target normalized

Iopamidol, Iodixanol-320

Interventions

Iopamidol, Iodixanol-320

Public preview

Source record

To compare Iopamidol injection 370 and Iodixanol 320 in evaluating Neutrophil Gelatinase-Associated Lipocalin (NGAL) in patients with moderate fall in eGFR

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin as New Biomarker in Patients With Moderate Fall in eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01136876

Status

COMPLETED

Phase

PHASE4

Sponsor

Bracco Diagnostics, Inc

Executive brief

Investment-Ready Snapshot

To compare Iopamidol injection 370 and Iodixanol 320 in evaluating Neutrophil Gelatinase-Associated Lipocalin (NGAL) in patients with moderate fall in eGFR

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedNov 04, 2020
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01136876

Indication

Coronary Artery Stenosis

Modality

small molecule

Target

Iopamidol, Iodixanol-320

Intervention

Iopamidol, Iodixanol-320

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.